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recognized that the virus interacts intimately with the lipid
machinery of the cell. Lipids are involved in almost all stages of
the HCV lifecycle beginning with viral entry and including RNA
replication, virion assembly and secretion of mature infectious
viral particles [1]. The HCV core protein associates directly with
cellular lipid droplets leading to recruitment of the non-struc-
tural (NS) proteins NS5A and NS3 to form the replicase complex,
which serves as a scaffold for the RNA-dependent-RNA polymer-
ase (NS5B) to begin replication of the viral genome [2]. Viral
assembly then takes place and seems to parallel the processing
of endogenous very low density lipoproteins (VLDL) with transfer
of apolipoprotein B (apoB) and then apoE to form infectious low-
density viral particles termed lipoviral particles (LVP) [3].
Impaired lipidation of viral particles results in production of
non-infectious high-density virions, whereas increased abun-
dance of LVP is associated with increased HCV infectivity [4].
The presence of increased apoE on the surface of LVP is associated
with increased infectivity, possibly by facilitating interaction
with lipoprotein receptors on hepatocytes [5]. ApoE may be
important for more than infectivity. ApoE expression inﬂuences
immune responses targeting lipid antigens and therefore its pres-
ence on HCV viral particles may be important for virus–host
interactions [6].
HCV infection triggers innate immune pathways leading to
the production of interferons and the establishment of an intra-
cellular antiviral state [7]. Successful viral clearance however
requires the subsequent emergence of a broad and potent HCV-
speciﬁc adaptive immune response [8]. If infection is not cleared
in the months following infection, the adaptive immune response
wanes and the infection progresses to a chronic state with stable
viral titers but progressive liver disease, after which viral clear-
ance does not occur without antiviral therapy [8]. Responses to
interferon-based treatment are largely dictated by the baseline
expression of intra-hepatic interferon-stimulated genes (ISGs)
[9]. Patients with low baseline ISG expression respond well to
interferon with high rates of viral clearance while those withJournal of Hepatology 20
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leading to interferon non-response and treatment failure
[10,11]. What controls the degree of ISG preactivation remains
poorly understood.
The identiﬁcation of single-nucleotide polymorphisms (SNPs)
near the IL28B gene that are strongly associated with spontaneous
[12] and treatment-induced viral clearance [13–15] raised thepos-
sibility that levels of interferon lambda (IL28B) were driving base-
line ISG expression. However, despite the long and growing list of
associations between the IL28B genotype andmany aspects of HCV
infection, the mechanisms underlying these relationships remain
remarkably elusive. Hepatic ISG expression is associated with
the IL28B genotype, howevermost reports have not found differing
levels of IL28B itself across the different genotypes [16,17]. Fur-
thermore, there are some seemingly paradoxical associations.
One might have expected that a robust interferon response at
baselinewould lead to higher rates of spontaneous viral clearance.
However, patients with the CC genotype have lower baseline ISG
expression [16–18], perhaps suggesting reduced interferon pro-
duction, yet have higher rates of spontaneous HCV clearance.
Despite their favourable response to therapy, CC patients also tend
to have higher baseline HCV RNA titres, a factor consistently
shown to be associatedwith interferon non-response [13]. Finally,
patients with the CC genotype have also been shown to have
higher cholesterol but less hepatic steatosis [19].
In this issue of the Journal, Sheridan and colleagues explore
possible links between interferon responses and HCV–lipid inter-
actions [20]. They hypothesize that HCV may take advantage of
the effects of interferon on lipid homeostasis. In a cohort of 72
patients with genotype 1 HCV infection, they evaluated the corre-
lations between levels of the infectious low-density HCV fraction
(LVP), lipid parameters (apoE, apoB and cholesterol) and the
response to interferon-based therapy. They also examined the
role of the IL28B genotype and measured serum levels of inter-
feron-gamma-inducible protein 10 (IP10) as a surrogate for ISG
expression. They ﬁrst show that, as might be expected, apoE lev-
els correlate well with the amount of lipid-rich LVP HCV but not
with the higher density, lipid-poor HCV fractions. Lower apoE
levels were found in patients with a good response to therapy
and in those with the treatment-favourable IL28B genotype
(CC). Finally, they found a modest correlation with levels of apoE
and IP10, but this was not replicated in a small validation cohort.12 vol. 57 j 3–5
Editorial
Based on these ﬁndings, the authors wonder if higher levels of
IP10, which they interpret to indicate greater interferon and
ISG activation, lead to more apoE, which in turn favours the more
infectious LVP form of the virus resulting in greater HCV infectiv-
ity and reduced treatment response.
An evaluation of the HCV fractions by IL28B genotype yielded
interesting results. The CC genotype was associated with higher
total HCV RNA levels, as has been shown before [13], but interest-
ingly the correlation was entirely driven by an association with
the less infectious non-LVP form of the virus. This may at least
partially explain the paradoxical association between the treat-
ment-responsive CC genotype and higher viral loads. The higher
viral loads seen in CC patients are composed of the less infectious
non-LVP virus and therefore do not negatively affect the response
to treatment. Presumably the association of higher viral levels
with poor treatment response relates to levels of the more infec-
tious LVP fraction and would likely disappear after controlling for
the IL28B genotype. The cohort in this study was too small for
such an analysis.
This study raises some interesting possibilities. The authors
suppose that endogenous interferon stimulates higher levels of
apoE, which ultimately promotes infectious LVP HCV and thus
reduces responses to interferon-based therapy. Although this is
an interesting hypothesis, it is premature to draw causal links.
The association between apoE levels and IP10wasmarginal at best
and IP10 is only amodest surrogate for ISGactivation [21]. Notably,
although therewas a trend, IP10 levels did not correlatewith treat-
ment outcome in this cohort and did not differ by IL28B genotype.
ApoE and LVP titre also did not differ by treatment response. How-
ever, the differences in levels of apoE, apoB and LDL by IL28B geno-
type were signiﬁcant. Rather than an explanation for treatment
non-response, the authors might have identiﬁed a factor relevant
to spontaneous viral clearance. The association between the CC
genotype and lower apoE but higher apoB and LDL levelswas quite
robust. If the CC genotype is associated with lower apoE levels and
therefore less infectious virus, this may explain why patients with
this genotype are more likely to clear infection. The infectiousness
of the virus is likely much more important at the time of acute
exposure when viral spread is rapidly progressing than during
interferon treatment. It may well be true that the LVP virus is less
interferon-responsive, in which case the hypothesis about treat-
ment may also be correct, but this has yet to be shown. The data
supporting LVP-related infectivity from this group [22] and others
[23] are strong andmay be very relevant to spontaneous clearance.
In fact, an explanation for spontaneous clearancewith theCCgeno-
type that does not require more interferon production would
potentially explain why these patients go on to have lower levels
of ISG preactivation, a paradox that has until now been unex-
plained. A theory allowing for lower interferon production in CC
patients, would also potentially explain the higher viral titres seen
with the CC genotype, whether LVP or non-LVP HCV.
To clarify whether the ﬁndings truly relate to interferon will
require some additional work. It would be helpful to know if apoE
is induced by exogenous (and ideally endogenous) interferon
directly and if so what mechanisms are involved. To support
the concept that higher apoE leads to interferon non-response,
it would be helpful to determine if there is a difference in inter-
feron sensitivity between the LVP and non-LVP viral fractions. It
would also be useful to delve further into the issue of spontane-
ous clearance and the association with the CC genotype. Do all
individuals with the CC genotype have lower apoE but higher4 Journal of Hepatology 2apoB and LDL levels or is this a phenomenon that requires the
presence of HCV, or possibly, as the authors suppose, endogenous
interferon? If the IL28B genotype affects apoE levels independent
of interferon, the question of the underlying mechanism arises
once again. Do patients who clear acute HCV have lower levels
of apoE and LVP? If so, would modulation of lipid balance at
the time of acute infection be a potential therapeutic strategy?
As with many provocative studies, the work by Sheridan and
colleagues may have raised more questions than it answers but
it is certainly a valuable contribution. These data offer some
potential explanations to some puzzling aspects of the compli-
cated but slowly emerging picture of HCV, lipids and interferon
responses. The possibility that interferon non-response is related
to effects on lipids is certainly intriguing and merits further study
and exploration of the potential relevance for spontaneous HCV
clearance, may be even more important.Conﬂict of interest
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